Last Updated: November 13, 2026

CLINICAL TRIALS PROFILE FOR CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

« Back to Dashboard

All Clinical Trials for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02452047 ↗	Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2015-08-21	The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (MK-7655A) versus colistimethate sodium+imipenem+cilastatin in the treatment of imipenem-resistant bacterial infections. Infections evaluated in the study will be hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), complicated intra-abdominal infection (cIAI), and complicated urinary tract infection (cUTI).
NCT04983901 ↗	Imipenem, Cilastatin Sodium, and Relebactam Monohydrate for the Treatment of Cancer Patients With Febrile Neutropenia	Not yet recruiting	M.D. Anderson Cancer Center	Phase 2	2021-08-10	This phase II trial studies the effect of imipenem-relebactam in treating patients with cancer who have a fever due to low white blood cell counts (febrile neutropenia). In this study, imipenem-relebactam will be compared to the standard-of-care treatment (cefepime, meropenem, or piperacillin/tazobactam) for the treatment of febrile neutropenia. Imipenem-relebactam is used to treat infections. Giving imipenem-relebactam may help to control febrile neutropenia in patients with cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Condition Name

Chart
Table

Condition Name for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Intervention	Trials
Hematopoietic and Lymphoid Cell Neoplasm	1
Malignant Solid Neoplasm	1
Bacterial Infections	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Intervention	Trials
Neoplasms	1
Infections	1
Infection	1
Communicable Diseases	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Trials by Country

Map
Table

Trials by Country for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Location	Trials
United States	3
Estonia	1
Italy	1
Latvia	1
Peru	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Location	Trials
Texas	1
New Jersey	1
California	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Clinical Trial Phase	Trials
Not yet recruiting	1
Completed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Sponsor Name

Chart
Table

Sponsor Name for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Sponsor	Trials
Merck Sharp & Dohme Corp.	1
M.D. Anderson Cancer Center	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Sponsor	Trials
Industry	1
Other	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.